Treatment of advanced stage diffuse, small non-cleaved cell lymphoma in childhood

Further experience with total therapy B

T. C. Griffin, W. P. Bowman, N. J. Winick, G. R. Buchanan

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Prior to the development of intensive treatments for patients with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL), the prognosis for such patients was dismal. A minority of patients attained long-term, disease-free survival. Since 1981, we have treated 28 children with advanced stage B-NHL with an intensive chemotherapeutic protocol, Total Therapy B. This regimen employs cycles of fractionated high-dose cyclophosphamide, doxorubicin, and vincristine alternating with sequential infusions of high-dose methotrexate and escalating doses of cytarabine, in addition to intensive intrathecal therapy. The planned duration of therapy is approximately 6 months. Two patients had B-cell acute lymphoblastic leukemia and 26 had stage III B-NHL; none had CNS involvement. The median age was 7 years. All 28 patients achieved complete remission (CR). Both patients with B-ALL and 21 of 26 with stage III B-NHL remain in CR, with a median follow-up of 51 months. Treatment failures included 3 patients with recurrent or progressive disease, 1 toxic death in CR, and 1 patient who developed a secondary mediastinal T-cell lymphoblastic lymphoma 4 1/2 years after the diagnosis of B-NHL. The 2- and 5- year event-free survival rates were 85.7 ± 6.6% (SE) and 79.6 ± 8.5%, respectively. Total Therapy B is a highly effective therapy for children with advanced stage B-NHL without CNS involvement.

Original languageEnglish (US)
Pages (from-to)393-399
Number of pages7
JournalMedical and Pediatric Oncology
Volume23
Issue number5
StatePublished - 1994

Fingerprint

Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Disease-Free Survival
T-Cell Lymphoma
Poisons
Cytarabine
Vincristine
Treatment Failure
Methotrexate
Doxorubicin
Cyclophosphamide
B-Lymphocytes
Survival Rate

Keywords

  • B-cell
  • Burkitt's lymphoma
  • leukemia
  • lymphoma
  • small noncleaved-cell

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Cite this

Treatment of advanced stage diffuse, small non-cleaved cell lymphoma in childhood : Further experience with total therapy B. / Griffin, T. C.; Bowman, W. P.; Winick, N. J.; Buchanan, G. R.

In: Medical and Pediatric Oncology, Vol. 23, No. 5, 1994, p. 393-399.

Research output: Contribution to journalArticle

@article{109604ff91394c1c8513594f40a0e48f,
title = "Treatment of advanced stage diffuse, small non-cleaved cell lymphoma in childhood: Further experience with total therapy B",
abstract = "Prior to the development of intensive treatments for patients with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL), the prognosis for such patients was dismal. A minority of patients attained long-term, disease-free survival. Since 1981, we have treated 28 children with advanced stage B-NHL with an intensive chemotherapeutic protocol, Total Therapy B. This regimen employs cycles of fractionated high-dose cyclophosphamide, doxorubicin, and vincristine alternating with sequential infusions of high-dose methotrexate and escalating doses of cytarabine, in addition to intensive intrathecal therapy. The planned duration of therapy is approximately 6 months. Two patients had B-cell acute lymphoblastic leukemia and 26 had stage III B-NHL; none had CNS involvement. The median age was 7 years. All 28 patients achieved complete remission (CR). Both patients with B-ALL and 21 of 26 with stage III B-NHL remain in CR, with a median follow-up of 51 months. Treatment failures included 3 patients with recurrent or progressive disease, 1 toxic death in CR, and 1 patient who developed a secondary mediastinal T-cell lymphoblastic lymphoma 4 1/2 years after the diagnosis of B-NHL. The 2- and 5- year event-free survival rates were 85.7 ± 6.6{\%} (SE) and 79.6 ± 8.5{\%}, respectively. Total Therapy B is a highly effective therapy for children with advanced stage B-NHL without CNS involvement.",
keywords = "B-cell, Burkitt's lymphoma, leukemia, lymphoma, small noncleaved-cell",
author = "Griffin, {T. C.} and Bowman, {W. P.} and Winick, {N. J.} and Buchanan, {G. R.}",
year = "1994",
language = "English (US)",
volume = "23",
pages = "393--399",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Treatment of advanced stage diffuse, small non-cleaved cell lymphoma in childhood

T2 - Further experience with total therapy B

AU - Griffin, T. C.

AU - Bowman, W. P.

AU - Winick, N. J.

AU - Buchanan, G. R.

PY - 1994

Y1 - 1994

N2 - Prior to the development of intensive treatments for patients with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL), the prognosis for such patients was dismal. A minority of patients attained long-term, disease-free survival. Since 1981, we have treated 28 children with advanced stage B-NHL with an intensive chemotherapeutic protocol, Total Therapy B. This regimen employs cycles of fractionated high-dose cyclophosphamide, doxorubicin, and vincristine alternating with sequential infusions of high-dose methotrexate and escalating doses of cytarabine, in addition to intensive intrathecal therapy. The planned duration of therapy is approximately 6 months. Two patients had B-cell acute lymphoblastic leukemia and 26 had stage III B-NHL; none had CNS involvement. The median age was 7 years. All 28 patients achieved complete remission (CR). Both patients with B-ALL and 21 of 26 with stage III B-NHL remain in CR, with a median follow-up of 51 months. Treatment failures included 3 patients with recurrent or progressive disease, 1 toxic death in CR, and 1 patient who developed a secondary mediastinal T-cell lymphoblastic lymphoma 4 1/2 years after the diagnosis of B-NHL. The 2- and 5- year event-free survival rates were 85.7 ± 6.6% (SE) and 79.6 ± 8.5%, respectively. Total Therapy B is a highly effective therapy for children with advanced stage B-NHL without CNS involvement.

AB - Prior to the development of intensive treatments for patients with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL), the prognosis for such patients was dismal. A minority of patients attained long-term, disease-free survival. Since 1981, we have treated 28 children with advanced stage B-NHL with an intensive chemotherapeutic protocol, Total Therapy B. This regimen employs cycles of fractionated high-dose cyclophosphamide, doxorubicin, and vincristine alternating with sequential infusions of high-dose methotrexate and escalating doses of cytarabine, in addition to intensive intrathecal therapy. The planned duration of therapy is approximately 6 months. Two patients had B-cell acute lymphoblastic leukemia and 26 had stage III B-NHL; none had CNS involvement. The median age was 7 years. All 28 patients achieved complete remission (CR). Both patients with B-ALL and 21 of 26 with stage III B-NHL remain in CR, with a median follow-up of 51 months. Treatment failures included 3 patients with recurrent or progressive disease, 1 toxic death in CR, and 1 patient who developed a secondary mediastinal T-cell lymphoblastic lymphoma 4 1/2 years after the diagnosis of B-NHL. The 2- and 5- year event-free survival rates were 85.7 ± 6.6% (SE) and 79.6 ± 8.5%, respectively. Total Therapy B is a highly effective therapy for children with advanced stage B-NHL without CNS involvement.

KW - B-cell

KW - Burkitt's lymphoma

KW - leukemia

KW - lymphoma

KW - small noncleaved-cell

UR - http://www.scopus.com/inward/record.url?scp=0028146199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028146199&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 393

EP - 399

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 5

ER -